M&A Deal Summary |
|
|---|---|
| Date | 2022-07-14 |
| Target | AffinityDNA |
| Sector | Life Science |
| Buyer(s) | Genetic Technologies |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1987 |
| Sector | Life Science |
| Revenue | 8M USD (2024) |
Genetic Technologies is a diversified molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer have clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. Genetic Technologies was founded in 1987 and is based in Maroochydore, Australia.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-07-19 |
EasyDNA
Elk Grove, California, United States EasyDNA is a provider of DNA testing and genetic testing. EasyDNA’s network of online retail sales platforms offers fast and affordable home DNA testing that is reliable and confidential. They also offer a number of lifestyle and health and wellbeing tests, and animal testing relating to allergies and tolerances. EasyDNA was founded in 2007 and is based in Elk Grove, California. |
Buy | $4M |
